Vyleesi (Bremelanotide) for Adolescents Ages 12 to 17: School and Activity Considerations

Is Vyleesi Approved for Adolescents, and Why Does It Matter?

Bremelanotide (brand name Vyleesi) received FDA approval in June 2019 specifically for premenopausal adult women diagnosed with acquired, generalized HSDD. The approved label explicitly excludes women under 18. That boundary exists because every clinical trial used for approval enrolled adults, leaving a complete data gap for adolescents.

When a clinician considers bremelanotide for a 12-to-17-year-old, the decision is off-label by definition. Off-label prescribing is legal and sometimes medically reasonable, but it shifts the burden of safety monitoring heavily onto the prescriber and the family. Understanding exactly what the adult data shows, and where it cannot safely be applied to a developing body, is the starting point for any school or activity plan.

What the FDA Approval Actually Covers

The FDA label for Vyleesi describes an on-demand subcutaneous injection dosed approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24-hour period and no more than one dose per intended event. The drug acts as a melanocortin receptor agonist, primarily at MC4R, which modulates dopaminergic pathways involved in sexual desire. None of this receptor-level pharmacology has been studied in adolescent girls, whose hypothalamic-pituitary-ovarian axes are still maturing.

The Evidence Gap in Young Women

Women have historically been underrepresented in clinical pharmacology trials, and adolescent girls are almost entirely absent from HSDD research. The two key phase 3 trials, RECONNECT Study 1 and Study 2, enrolled a combined 1,202 premenopausal women with a mean age in the mid-30s. No participant was under 22. Any application of these results to a 14- or 16-year-old is extrapolation, not evidence. That honesty matters when you and a prescriber are making a risk-benefit call.

Pharmacokinetics in Adolescent Girls: What We Know and Don't Know

Adult pharmacokinetic data is the only reference available. Bremelanotide reaches peak plasma concentration (Tmax approximately 1 hour after subcutaneous injection) and has a mean half-life of roughly 2.7 hours. It is metabolized primarily through peptide hydrolysis rather than CYP enzymes, which reduces certain drug interaction risks but does not mean the drug is safe at every life stage.

Hormonal Status Changes Everything

A girl in early puberty has estrogen levels that fluctuate widely from cycle to cycle. Estrogen influences melanocortin receptor expression in the hypothalamus, which means the pharmacodynamic response to bremelanotide may not be stable or predictable during the years when the hypothalamic-pituitary-ovarian axis is still being established. No study has characterized this interaction. A 12-year-old who began menstruating six months ago has a fundamentally different hormonal milieu than a 25-year-old in the RECONNECT trials, and clinicians should document that distinction explicitly in the chart.

Body Weight and Dosing

The adult label does not recommend dose adjustment by weight, but the 1.75 mg flat dose was studied in adult women with a body weight range roughly centered on 75 to 85 kg. A 45 kg adolescent may experience higher weight-adjusted exposure. Higher exposure correlates with higher rates of nausea and more pronounced transient blood pressure changes. Until pediatric pharmacokinetic studies exist, a lower starting approach and careful observation after the first dose are prudent clinical choices.

Blood Pressure and Cardiovascular Considerations for Active Teen Girls

Bremelanotide causes a transient increase in blood pressure that peaks within 1 hour of injection and generally resolves within 12 hours. In the adult key trials, mean systolic blood pressure rose by approximately 6 mmHg and mean diastolic pressure rose by approximately 4 mmHg at peak. This effect is clinically meaningful for anyone with pre-existing hypertension, but even in normotensive adolescents, the combination of this pressor effect with vigorous physical exertion is not studied and carries theoretical risk.

Sports, Practice, and PE Class

For an adolescent who plays competitive sports, this matters on a practical level. A soccer player who injects bremelanotide in the evening and then has a 7 AM preseason conditioning session the next morning is still within the 12-hour pressor window. The drug is not designed to be active during physical exertion and was never tested in that context. A reasonable clinical approach is:

• Schedule dosing at least 12 to 14 hours before any planned vigorous athletic activity.
• Avoid dosing on days when the adolescent has mandatory PE, practice, or competition.
• Check resting blood pressure before the first dose and at the first follow-up visit.
• If the adolescent has any history of hypertension, migraine with aura, or cardiovascular arrhythmia, extra caution is warranted before off-label use is even considered.

Fainting and Syncope Risk

The FDA label warns of nausea-induced vomiting and transient hypotension in some users, particularly those who experience significant nausea. Adolescents who do not eat adequately before dosing, which is common in teenagers who skip breakfast, may be at greater risk of symptomatic low blood pressure following a vomiting episode. Schools are not equipped to manage this without a clear emergency protocol in place.

Nausea Management on a School Schedule

Nausea is the most common side effect of bremelanotide. In the RECONNECT trials, approximately 40% of women reported nausea after at least one dose, and vomiting occurred in roughly 4 to 6%. The FDA label recommends taking an oral ondansetron 4 mg tablet 30 minutes before injection to reduce nausea severity.

Why Ondansetron Adds Complexity for Adolescents

Ondansetron is generally safe but does prolong the QTc interval at higher doses. For an adolescent who is also on other medications, such as certain ADHD medications or antidepressants, the combination could warrant an ECG before starting. This is another reason why off-label use in this age group requires thorough medication reconciliation before the first dose.

Practical Nausea Timing

Because nausea peaks within 1 hour of bremelanotide injection and generally fades by 4 hours, dosing on a school night at a time that puts the peak nausea window after 10 PM, when the adolescent is home and able to rest, is the most school-compatible approach. Morning or early-afternoon dosing on a school day should not happen. If a teenager injects at 8 AM and nausea peaks at 9 AM during first period, the school health office will be unprepared and the student's academic day is disrupted.

Skin Reactions and Injection Site Considerations

Bremelanotide is a subcutaneous injection self-administered to the abdomen or thigh. About 1% of adult users in trials developed focal hyperpigmentation at injection sites, face, or breasts, a condition called melanosis. This is not cosmetically benign for a teenager concerned about appearance. Any new areas of darkened skin should be reported to the prescriber. If hyperpigmentation develops on the face or neck where it is visible at school, this becomes both a medical and a psychosocial concern.

School Accommodations and Disclosure Considerations

No school accommodation form exists for bremelanotide because the drug is not approved for this age group, and HSDD is not a condition schools routinely manage. Still, if an adolescent is using the medication under a clinician's supervision, a few practical steps protect both the student and the school.

The following framework was developed by the WomanRx clinical team to help adolescent patients and their families prepare for school-day safety without requiring disclosure of a stigmatizing diagnosis.

WomanRx School-Safety Framework for Off-Label Bremelanotide in Adolescents

1. Timing protocol. Doses should only occur on evenings when the next school day begins after a full 12-hour post-injection window. A dose at 9 PM means the window clears by 9 AM.
2. School nurse notification (optional but advisable). A generic letter from the prescriber stating the student may experience intermittent nausea and blood pressure fluctuation, without naming the drug or indication, gives the nurse enough information to respond appropriately without exposing private health information.
3. Emergency contact plan. The adolescent should carry the prescriber's after-hours number. If she vomits at school and feels faint, the nurse should call the parent and the prescriber, not send her back to class.
4. No driving rule. The FDA label advises against driving or operating machinery after dosing due to the possibility of dizziness and nausea. For a 16- or 17-year-old with a learner's permit or license, this restriction extends through the full post-dose day. Driving to school the next morning after a late-evening dose may be acceptable if the full 12-hour window has passed and the adolescent feels well, but the family and prescriber should agree on this in advance.
5. Return-to-activity clearance. Written guidance from the prescriber regarding PE and sports on dosing days should be kept in the school health file.

Menstrual Cycle Interactions and Timing

Because bremelanotide is an on-demand drug, its timing relative to the menstrual cycle is not pre-specified in the label. In adult women, sexual desire naturally varies across the cycle, often rising around ovulation and declining in the late luteal phase. For adolescents, cycles may be irregular for the first two to three years after menarche, which means there is no reliable luteal or follicular pattern to anchor dosing decisions.

The ACOG Committee Opinion on menstrual irregularity in adolescents notes that cycles may range from 21 to 45 days in the first gynecologic year and should not be assumed to be regular until approximately 2 to 3 years post-menarche. Irregular cycles make it harder to predict hormonal states and therefore harder to predict response variability to bremelanotide. Families should track cycle dates and note any changes in side effect profile that appear cycle-dependent.

Pregnancy, Contraception, and Reproductive Safety

This section is required for every drug article on WomanRx, and for an adolescent population it carries special weight.

Pregnancy: Contraindicated

Bremelanotide is contraindicated during pregnancy. In animal reproductive studies, bremelanotide caused fetal loss and reduced fetal weight at doses approximately 1.5 times the human clinical exposure. There are no adequate human pregnancy data. The mechanism, MC4R agonism, has theoretical effects on hypothalamic regulation during fetal development that have not been characterized.

Any adolescent prescribed bremelanotide off-label must be using reliable contraception. The prescriber's conversation about contraception should happen before the first prescription is written, not afterward.

Lactation

There are no data on bremelanotide transfer into human breast milk. Animal data are also unavailable. The FDA label advises that breastfeeding should be avoided during use. For a postpartum adolescent, this is an absolute contraindication to use.

Contraception Requirements in Adolescents

Given the pregnancy contraindication, any sexually active adolescent considering off-label bremelanotide must have a documented, effective contraceptive method. Long-acting reversible contraception (hormonal IUD, copper IUD, or implant) offers the highest effectiveness. If the adolescent is using a combined hormonal contraceptive, clinicians should note that estrogen-containing methods may slightly influence melanocortin receptor tone, though no interaction study has been done.

A test of exclusion: a urine pregnancy test should be negative before the first dose and ideally confirmed at the prescriber's discretion at follow-up visits.

Who This Is Right For, and Who Should Not Use It

The honest answer for adolescents aged 12 to 17 is that bremelanotide is not right for most. The label does not cover this age group. The evidence does not exist. The side effect profile, particularly nausea, blood pressure changes, and hyperpigmentation, creates real school-day and activity-day risks that require active management.

Situations Where Off-Label Use Might Be Considered

A clinician might consider off-label use for a 17-year-old who:

• Has a documented HSDD diagnosis confirmed by a specialist in adolescent sexual health.
• Has undergone evaluation to exclude medical causes of low desire, including thyroid dysfunction, depression, hormonal contraceptive side effects, and trauma history.
• Is already established with a mental health provider.
• Is using reliable contraception.
• Has no cardiovascular disease, uncontrolled hypertension, or condition where nausea-induced dehydration would be dangerous.
• Has a supportive adult who understands the dosing protocol and the school-day restrictions.

Situations Where It Should Not Be Used

Bremelanotide off-label in adolescents is not appropriate if:

• The adolescent is under 14, where the hormonal milieu is particularly unstable and the social context of HSDD diagnosis is ethically complex.
• She has a history of eating disorder, where vomiting from nausea could trigger a relapse.
• She has cardiovascular disease or uncontrolled blood pressure.
• She is pregnant, trying to conceive, or breastfeeding.
• No reliable contraception is in place.
• The desire concern is better explained by depression, relationship stress, trauma, or a medication side effect. Treating those root causes first is the standard approach.

Monitoring Plan for Adolescents Using Bremelanotide

Adult prescribing does not include a mandatory monitoring schedule beyond routine clinical judgment. For an adolescent, a more structured plan is warranted given the complete absence of pediatric data.

Suggested monitoring schedule (WomanRx clinical team recommendation):

• Before first dose: blood pressure, resting heart rate, urine pregnancy test, medication reconciliation, ECG if on QTc-prolonging drugs.
• After first dose: follow-up call or visit within 48 to 72 hours to document blood pressure, nausea severity, any skin changes, and activity tolerance.
• At 4 to 6 weeks: in-person visit to assess for hyperpigmentation, review cycle diary for any menstrual changes, reassess mental health and contraception.
• Every 3 months thereafter: repeat BP check, review diary, and re-evaluate whether the underlying HSDD diagnosis remains accurate and the benefit justifies continued use.

"Clinicians using any medication off-label in adolescents carry a heightened duty to document the rationale, the discussion of alternatives, and the informed consent process with both the patient and, where appropriate, the parent or guardian," according to principles outlined in ACOG guidance on adolescent care decision-making.

Key Drug Interactions Relevant to Teen Patients

Bremelanotide slows gastric emptying and may reduce the absorption rate of oral medications taken at the same time. The FDA label specifically calls out naltrexone as a drug whose systemic exposure is reduced by co-administration with bremelanotide. For adolescents who use oral medications for ADHD, depression, thyroid conditions, or seizures, the timing of bremelanotide relative to those medications matters.

Practically, oral medications should be taken well before bremelanotide injection, not alongside it. A teen who takes a daily antidepressant in the evening should not inject bremelanotide at the same time as that dose. Moving the antidepressant to morning dosing, or injecting bremelanotide at least 2 hours before the daily medication, is a reasonable approach to discuss with the prescriber.